RINVOQ® (Upadacitinib) Receives Its Sixth U.S. FDA Approval
RINVOQ is now approved as the first and only oral JAK inhibitor for adults with active non-radiographic axial spondyloarthritis (nr-axSpA)RINVOQ i...
Source: businessinsider.com
Total Back Pain News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Total Back Pain. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Total Back Pain Today - Breaking & Trending Today
RINVOQ® (upadacitinib) Approved by U.S. FDA as an Oral Treatment for Adults with Active Ankylosing Spondylitis
Across the two pivotal trials, RINVOQ delivered rapid and meaningful disease control with nearly half of ankylosing spondylitis (AS) patients achi...
Source: businessinsider.com
RINVOQ® (upadacitinib) Approved by U.S. FDA as an Oral Treatment for Adults with Active Ankylosing Spondylitis
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib; 15 mg, once daily) for...
Source: prnewswire.com
AbbVie's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from the first of two studies of the Phase 3 SELECT-AXIS 2 clinical trial...
Source: prnewswire.com
AbbVie's Upadacitinib Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis
ABBVie today announced positive top-line results from Study 2 of the Phase 3 SELECT-AXIS 2 clinical trial in adults with active non-radiographic axial spondyloarthritis showing upadacitinib met the primary endpoint of Assessment in SpondyloArthritis International Society 40 response and the majority of ranked secondary endpoints at week 14. 1 Significantly more upadacitinib-treated patients achieved ASAS40 ...
Source: investingnews.com